Élan
 |
|
| Public | |
| Traded as | : ELN |
| Industry | Biotechnology |
| Fate | Acquired by Perrigo |
| Founded | Athlone, County Roscommon, Ireland (1969) |
| Defunct | 2013 |
| Headquarters | Dublin, Ireland |
|
Key people
|
Robert Ingram, Chairman Kelly Martin, CEO |
| Products |
PRIALT (ziconotide) NANOCRYSTAL technology In pipeline: TYSABRI (natalizumab) AZACTAM (aztreonam for injection, USP) MAXIPIME (cefepime hydrochloride) for Injection |
| Revenue | $0.2 million USD (2012) |
| $(366.9) million USD (2012) | |
| $(363.9) million USD (2012) | |
| Website | elan |
Élan Corporation plc was a major drugs firm based in Dublin, Ireland, which had major interests in the United States. It was listed on the as ELN, the as ELN.I, and the as ELN.L. In 2013, the company merged with Perrigo to form Perrigo Company PLC.
The company was founded in Ireland in 1969. In the late 1990s its value on the reached over €20bn. However, in 2002 an accounting scandal and investor reactions to the global slump, caused a major devaluation resulting in a price slump of over 90%. Since then the company has regained its growth path under the reign of a new American CEO Kelly Martin. In July 2010, Élan was fined $203m for its marketing of epilepsy drugs.
In February 2013 Élan decided to dispose of the rights to sell Tysabri to Biogen Idec for $3.25 billion.
In neurology, Élan is focused on building upon its research and experience in the area of neuropathologies such as Alzheimer’s disease, where the company’s efforts include programs focused on small molecule inhibitors of beta secretase and gamma secretase, enzymes whose actions are thought to affect the accumulation of the amyloid plaques found in the brains of patients with Alzheimer’s disease. An example of such a molecule is semagacestat. Élan is also studying other neurodegenerative diseases, such as Parkinson's disease. Élan, in collaboration with Wyeth, is currently conducting a Phase III clinical trial for bapineuzumab, an experimental humanized monoclonal antibody with a targeted indication of immunotherapeutic treatment of mild to moderate Alzheimer’s disease. This humanized monoclonal antibody is designed and engineered to clear the neurotoxic beta-amyloid peptide that accumulates in the brains of patients with Alzheimer’s disease. Although initial results from an earlier Phase II clinical trial presented in July 2008 were inconclusive, Élan is hopeful that bapineuzumab will prove successful in the treatment of this disease.
...
Wikipedia